K. Gurova

FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair
20241 citationsauthor #4
FACT inhibitor CBL0137, administered in an optimized schedule, potentiates radiation therapy for glioblastoma by suppressing DNA damage repair
20240 citationsauthor #4
Targeting Features of Curaxin CBL0137 on Hematological Malignancies In Vitro and In Vivo
20236 citationsauthor #9
Comparison of cell response to chromatin and DNA damage
202310 citationsauthor #9
Can aggressive cancers be identified by the “aggressiveness” of their chromatin?
20228 citationsauthor #1
CPSF3 inhibition blocks pancreatic cancer cell proliferation through disruption of core histone processing
20221 citationsauthor #12
Abstract B042: Inhibition of CPSF3 attenuates pancreatic cancer cell proliferation through disruption of histone processing
20220 citationsauthor #12
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
202212 citationsauthor #18
Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition
20220 citationsauthor #7
FACT maintains nucleosomes during transcription and stem cell viability in adult mice
20228 citationsauthor #8
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy
202113 citationsauthor #11
HGG-09. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION IN DIPG
20210 citationsauthor #19
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma
202122 citationsauthor #36
FACT-mediated maintenance of chromatin integrity during transcription is essential for viability of mammalian stem cells
20211 citationsauthor #7
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
202136 citationsauthor #21
Alkaloid-rich fraction of Ervatamia coronaria sensitizes colorectal cancer through modulating AMPK and mTOR signalling pathways.
202115 citationsauthor #13
DIPG-27. TARGETING FACILITATES CHROMATIN TRANSCRIPTION (FACT) AS A NOVEL STRATEGY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) THAT ENHANCES RESPONSE TO HISTONE DEACETYLASE (HDAC) INHIBITION
20200 citationsauthor #21
Dual Targeting of the Epigenome Via Facilitates Chromatin Transcription Complex (FACT) and Histone Deacetylase is a Potent Treatment Strategy for DIPG
20200 citationsauthor #20
Abstract 1747: Induction of nucleosome disassembly with small molecules as a novel anti-cancer approach
20200 citationsauthor #4
The 3D Genome as a Target for Anticancer Therapy.
202026 citationsauthor #2
Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors.
202010 citationsauthor #12
Abstract IA13: Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies
20200 citationsauthor #19
Abstract 4496: Induction of immunogenicity in tumor cells by small molecule drugs that destabilize nucleosomes
20200 citationsauthor #4
Histone chaperone FACT is essential to overcome replication stress in mammalian cells
202025 citationsauthor #5
A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks.
20203 citationsauthor #6
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia
202036 citationsauthor #14
Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
20200 citationsauthor #14
Abstract 1755: Chromatin trapping is a key factor for anticancer cytotoxicity of DNA-binding small molecule drugs
20191 citationsauthor #8
Histone Chaperone FACT and Curaxins: Effects on Genome Structure and Function.
201916 citationsauthor #5
Curaxin CBL0137 has the potential to reverse HIV‐1 latency
20197 citationsauthor #7
The anti-cancer drugs curaxins target spatial genome organization
201955 citationsauthor #10
Abstract 5193: Conditional knockout of histone chaperone FACT in mice: Consequences for normal tissues
20190 citationsauthor #5
Influence of DNA-binding compounds with cancer preventive activity on the mechanisms of gene expression regulation
20195 citationsauthor #7
Activation of interferon-α signaling by resveratrol, genistein and quercetin
20193 citationsauthor #8
Prevention of Colorectal Carcinogenesis by DNA-Binding Small-Molecule Curaxin CBL0137 Involves Suppression of Wnt Signaling
20199 citationsauthor #18
Abstract 2866: Anticancer effect of a new cyclic peptide ALOS4 is associated with its systemic anti-inflammatory activity
20180 citationsauthor #13
Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene
201824 citationsauthor #5
Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.
201860 citationsauthor #8
TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells
201840 citationsauthor #15
PO-464 Influence of natural DNA-binding compounds with cancer preventive activity on chromatin structure
20180 citationsauthor #5
Chromatin Stability as a Target for Cancer Treatment
201825 citationsauthor #1
PO-459 Systemic anti-inflammatory effect of a new anticancer cyclic peptide ALOS4
20180 citationsauthor #8
Prevention of Chromatin Destabilization by FACT Is Crucial for Malignant Transformation
201815 citationsauthor #8
Structure and function of the histone chaperone FACT - Resolving FACTual issues.
201897 citationsauthor #1
FACT is a sensor of DNA torsional stress in eukaryotic cells
201788 citationsauthor #15
Prognostic value of histone chaperone FACT subunits expression in breast cancer
201719 citationsauthor #7
TRAIN in response to treatment with anti-cancer small molecule destabilizing chromatin
20170 citationsauthor #14
Inhibition of the Histone Chaperone, FACT (Facilitates Chromatin Transcription) By the Novel Small Molecule CBL0137 (Curaxin) Shows Promising Efficacy in Pre-Clinical Models of Acute Myeloid Leukemia
20171 citationsauthor #4
Transcription of Repeats Activates INterferon (TRAIN) in response to chromatin destabilization induced with anti-cancer small molecule
20171 citationsauthor #14
Abstract 809: A novel woodchuck model of hepatic artery infusion (HAI) with FACT complex targeted drug CBL0137
20170 citationsauthor #5
Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells
201746 citationsauthor #8
Abstract 13: Chromatin unfolding small molecules as a novel type of anticancer agents
20176 citationsauthor #1
Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation
201739 citationsauthor #7
Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma
20161 citationsauthor #8
Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
201665 citationsauthor #8
Inhibition of the FACT Complex Reduces Transcription from the Human Cytomegalovirus Major Immediate Early Promoter in Models of Lytic and Latent Replication
201623 citationsauthor #3
Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.
201620 citationsauthor #9
ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin
20162 citationsauthor #13
Novel synthetic cyclic integrin αvβ3 binding peptide ALOS4: antitumor activity in mouse melanoma models
201610 citationsauthor #10
Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma
201661 citationsauthor #5
FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency*
201546 citationsauthor #7
Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells
20150 citationsauthor #7
Abstract PR09: MYCN and is a therapeutic target in neuroblastoma
20150 citationsauthor #29
STEM-21DISRUPTION OF FACILITATES CHROMATIN TRANSCRIPTION (FACT) SYNERGIZES WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITION AND PREFERENTIALLY TARGETS GLIOBLASTOMA STEM CELLS
20150 citationsauthor #6
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
2015128 citationsauthor #35
Abstract 1611: The FACT histone chaperone complex is highly expressed in aggressive drug refractory childhood cancers and the anti-FACT compound CBL0137 represents a highly promising therapeutic approach in this setting
20150 citationsauthor #15
Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer
201459 citationsauthor #2
Cancer Biology and Signal Transduction Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT , NFk B , and Cell-Cycle Progression in Non – Small Cell Lung Cancer
20140 citationsauthor #2
HIGH GRADE GLIOMAS AND DIPG
20140 citationsauthor #229
Small-Molecule Xenomycins Inhibit All Stages of the Plasmodium Life Cycle
20149 citationsauthor #6
Abstract 815: CBL0137 demonstrates significant antitumor activity against hepatocellular carcinoma alone and in combination with sorafenib
20140 citationsauthor #4
422 CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in pre-clinical models of neuroblastoma
20141 citationsauthor #12
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer
201451 citationsauthor #10
Abstract 800: Synergistic effects of CBL0137 and gemcitabine against non-small cell lung and pancreatic cancer xenografts
20140 citationsauthor #5
Level of SSRP1 in Cancer as a Prognostic Marker of Aggressive Disease
20133 citationsauthor #1
Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers.
2013126 citationsauthor #18
Abstract 2759: Anticancer compound curaxin CBL0137, that simultaneously suppresses NF-κB and activates p53, is highly effective in two independent mouse models of neuroblastoma.
20132 citationsauthor #6
ET-001. HIGH LEVELS OF TIMP-1 CAN REDUCE THE EFFECT OF TOPOISOMERASE INHIBITORS ON GLIOBLASTOMA CELLS THERAPEUTICALLY TARGETING ATRX DEFICIENCY IN LOWER-GRADE ASTROCYTOMA
20130 citationsauthor #5
P (cid:1) 0046 CURAXIN CBL0137 DEMONSTRATES SIGNIFICANT ANTITUMOR ACTIVITYAGAINST FACT-POSITIVE PATIENT-DERIVED PANCREATIC DUCTAL ADENOCARCINOMA
20130 citationsauthor #10
P-0046CURAXIN CBL0137 DEMONSTRATES SIGNIFICANT ANTITUMOR ACTIVITY AGAINST FACT-POSITIVE PATIENT-DERIVED PANCREATIC DUCTAL ADENOCARCINOMA
20130 citationsauthor #10
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY
20132 citationsauthor #35
Abstract 5043: The facilitates chromatin transcription (FACT) protein complex promotes neuroblastoma tumor initiation.
20130 citationsauthor #8
Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells
201354 citationsauthor #7
Abstract A263: Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer.
20130 citationsauthor #2
Abstract 3843: Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice
20120 citationsauthor #1
Targeting FACT Complex Suppresses Mammary Tumorigenesis in Her2/neu Transgenic Mice
201257 citationsauthor #13
Inflammation and p53: A Tale of Two Stresses.
2011195 citationsauthor #2
Gasparian and Activate p 53 by Targeting FACT B κ Curaxins : Anticancer Compounds That Simultaneously Suppress NF -
20110 citationsauthor #17
Curaxins: Anticancer Compounds That Simultaneously Suppress NF-κB and Activate p53 by Targeting FACT
2011223 citationsauthor #17
Abstract SY18-02: Targeting transcriptional regulators for simultaneous modulation of p53 and NF-κB in cancer treatment
20100 citationsauthor #1
Inhibition of Encephalomyocarditis Virus and Poliovirus Replication by Quinacrine: Implications for the Design and Discovery of Novel Antiviral Drugs
201036 citationsauthor #7
Abstract LB-166: Characterization of a novel class of carbazole based radiation sensitizers
20100 citationsauthor #7
Anti-malaria drug blocks proteotoxic stress response:
20101 citationsauthor #5
Anti-malaria drug blocks proteotoxic stress response: Anti-cancer implications
200954 citationsauthor #5
9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-κB and p53 pathways
2009113 citationsauthor #8
Carbazolforbindelser and therapeutic uses of the compounds
20090 citationsauthor #6
Small Molecule MRP1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Model of Neuroblastoma
20097 citationsauthor #13
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
2009101 citationsauthor #12
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer
200922 citationsauthor #9
Chemotherapy in Mouse Models of Neuroblastoma Inhibitor Reversan Increases the Therapeutic Index of Associated Protein 1 − Small-Molecule Multidrug Resistance
20090 citationsauthor #12

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT